RxDoctor Payments Data

Judd Boczko, MD

Urology · White Plains, NYNPI 1740258169

Payments from drug & device makers

$1,845in general payments, 2019–2025

Across 52 payments — averaging $35.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SRS Medical Systems, Inc.$750
  • Acerus Pharmaceuticals Corporation$608
  • Olympus America Inc.$141
  • EDAP Technomed Inc$66
  • Neotract Inc.$66
  • Sumitomo Pharma America, Inc.$57
  • plus $157 from 6 others
$12,000in research payments, 2019–2025

Across 1 payment — averaging $12,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • SRS Medical Systems, Inc.$12K

What the payments were for

  • Consulting fees$75041%
  • Food & beverage$1,09559%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,845 in reported general payments places this provider in the 40th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$543,448
Medicare patients
851
Services billed
5,825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron121$104,323
Tamsulosin Hcl1,682$22,502
Finasteride966$13,518
Silodosin113$12,479
Trospium Chloride114$12,169
Mirabegron ErMirabegron19$12,167
Oxybutynin Chloride ErOxybutynin Chloride329$10,158
Potassium Citrate ErPotassium Citrate82$8,832
Solifenacin Succinate80$7,982
Estradiol81$7,265
Trospium Chloride ErTrospium Chloride13$4,443
Alfuzosin Hcl ErAlfuzosin Hcl78$2,522
Dutasteride51$2,223
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst75$972
Cefdinir115$896

Paid to pharmacies, not to this prescriber.

Other urology in White Plains

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →